Efavirenz in an obese HIV-infected patient – a report and an in vitro–in vivo extrapolation model indicate risk of underdosing

Details

Request a copyRequest a copy
Serval ID
serval:BIB_2B532405FD6A
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
UNIL/CHUV
Title
Efavirenz in an obese HIV-infected patient – a report and an in vitro–in vivo extrapolation model indicate risk of underdosing
Journal
Antiviral therapy
Author(s)
de Roche Mirjam, Siccardi Marco, Stoeckle Marcel, Livio Françoise, Back David, Battegay Manuel, Marzolini Catia
ISSN
2040-2058 (Electronic))
ISSN-L
1359-6535
Publication state
Published
Issued date
2012
Peer-reviewed
Oui
Volume
17
Number
7
Pages
1381-1384
Language
english
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Abstract
Here, we report suboptimal efavirenz exposure in an obese patient treated with the standard 600 mg dose. Tripling the dose allowed attainment of therapeutic efavirenz concentrations. We developed an in vitro-in vivo extrapolation model to quantify dose requirements in obese individuals. Obesity represents a risk factor for antiretroviral therapy underdosing.
Keywords
Benzoxazines/administration & dosage, Benzoxazines/pharmacokinetics, Body Mass Index, Computer Simulation, Drug Dosage Calculations, Drug Monitoring/methods, HIV/pathogenicity, HIV Infections/drug therapy, HIV Infections/pathology, HIV Infections/virology, Humans, Male, Middle Aged, Obesity/pathology, RNA, Viral/blood, Reverse Transcriptase Inhibitors/administration & dosage, Reverse Transcriptase Inhibitors/pharmacokinetics, Risk Factors, Viral Load
OAI-PMH
oai:serval.unil.ch:BIB_2B532405FD6A
DOI
10.3851/imp2107
Pubmed
22910127
Web of science
000311240000020
Create date
13/12/2012 19:50
Last modification date
25/08/2023 19:44
Usage data